🏛️ Verified NIH Record • Updated 2026-08-21
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE) (NCT04084080)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: University of Pittsburgh
🩺 Plain-English Summary (8th-Grade Level)
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
Who can join: Review the eligibility criteria below.
Location: University of Alabama — Tuscaloosa, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- University of Alabama — Tuscaloosa, Alabama
- UCSF Benioff Children's Hospital Oakland — Oakland, California
- Howard University Center for Sickle Cell Disease — Washington D.C., District of Columbia
- Emory University — Atlanta, Georgia
- University of Illinois at Chicago — Chicago, Illinois
- University of Maryland — Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland
- Boston Medical Center — Boston, Massachusetts
- Washington University-St. Louis — St Louis, Missouri
- Icahn School of Medicine at Mount Sinai — New York, New York
- Montefiore Medical Center — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Atrium Health — Charlotte, North Carolina
- Duke University — Durham, North Carolina
- East Carolina University — Greenville, North Carolina
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Ohio State University — Columbus, Ohio
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- University of Texas Health Science Center at Houston — Houston, Texas
- Virginia Commonwealth University — Richmond, Virginia
- Hemorio — Rio de Janeiro,
- Kremlin-Bicêtre — Créteil,
- Henri Mondor Hopital — Paris,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Sickle Cell Disease
- Kidney Function in Sickle Cell Anemia — Chapel Hill, North Carolina
- BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease — Birmingham, Alabama
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease — Bethesda, Maryland
- Acupressure in Patients With Sickle Cell Disease — Irvine, California
- Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) — Chicago, Illinois
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) — Charlotte, North Carolina
Explore by condition: All Sickle Cell Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.